Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03474614 · ClinicalTrials.gov registry record · Phase 2
Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation
A Phase 2 study, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT03474614 is a Phase 2 study that was terminated before completion, run by St. Joseph's Hospital and Medical Center, Phoenix. The registered enrollment target is 4 participants.
The verdict
NCT03474614, a Phase 2 study, was terminated before completion, sponsored by St. Joseph's Hospital and Medical Center, Phoenix.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. Patients will be randomized into two groups: A Treatment group of ten (n=10) patients that will receive oral propranolol at a dose of 60mg per day (one 60mg ER capsule per day) for 7- to 10-days prior to surgery plus their usual medications, and a Control group of 10 (n=10) patients will receive only their routine medications. Currently, the only active treatment alternative for symptomatic cerebral cavernous malformations is surgery. A control group is required to allow for a semi-quantitative comparison with mRNA and miRNA levels in the treatment group.
Interventions
- DRUG Propranolol
- GENETIC DNA and RNA Analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2018-01-24 |
| Est. Completion | 2021-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03474614
The ClinicalTrials.gov registry entry for NCT03474614 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Propranolol is the first listed.
NCT03474614 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03474614 about?
NCT03474614 is a clinical study titled "Effect of Oral Propranolol on mRNA Expresssion in Symptomatic Cavernous Malformation". This is a single center, randomized, trial that will enroll twenty (n=20) patients with a diagnosis of symptomatic cavernous malformations who are planned candidates for surgical resection by one of the investigators, and who meet all of the inclusion and exclusion criteria. Patients will be randomi...
What is the current status of trial NCT03474614?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2018-01-24. Estimated completion is 2021-02-11.
What interventions are being tested in trial NCT03474614?
The interventions under investigation include: Propranolol (DRUG), DNA and RNA Analysis (GENETIC).
Who is sponsoring clinical trial NCT03474614?
This trial is sponsored by St. Joseph's Hospital and Medical Center, Phoenix, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.